# DefEYE Secures Investment from ExSight Ventures in $12M Seed Round

> financing · REPORTED · 2025-11-06

DefEYE received an investment from ExSight Ventures as part of its $12 million Series Seed Preferred Equity funding round, alongside a strategic in-kind investment and exclusive license from Celularity. The proceeds are intended to scale a portfolio of decellularized biologic solutions for eye care.

About DefEYE, Inc.: DefEYE is a privately held ophthalmic biologics company that develops decellularized placental-based tissue solutions for ocular surface disease, pterygium surgery, and other surgical eye care applications.

- Company: DefEYE
- Sector: medical_device
- Primary source: https://finance.yahoo.com/news/defeye-inc-announces-investment-exsight-130000623.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.